INDICES> Haemodialysis adjustment for cytotoxics (cont)

["lo@euronet.nl" <lo@euronet.nl>]

As a clinician I have a feeling that this query basically touches a 
medical ethical issue and has nothing to do with pharmacokinetics or 
drug monitoring: Should one treat a patient with terminal renal 
failure on haemodialysis, apparently suffering from a terminal 
ovarian carcinoma, with such highly toxic oncolytics? What do the 
physicians expect? If the patient had received a precious renal 
transplant one should not even have considered such use. Giving a 
"scientific" answer seems to me highly unrealistic. I would be very 
upset if a similar question would be asked if the patient was my 
wife. Humans are not experimental animals.
Sorry for this intervention. Best wishes.
Dr.L.Offerhaus
Koedijklaan 1a, NL-1406 KW Bussum, The Netherlands
Phone: 0031-35-6923288  Fax: 0031-35-6923290
E-mail: LO@EURONET.NL; CompuServe 71530,15
EJCP Only: POB 75552, NL-1070AN Amsterdam


--
Send mail for the `INDICES' conference to `indices@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to:  `owner-indices@usa.healthnet.org'.